Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 埃罗替尼 催眠药 内科学 阿法替尼 肿瘤科 临床终点 人口 安慰剂 肺癌 盐酸厄洛替尼 表皮生长因子受体 临床试验 癌症 病理 替代医学 环境卫生
作者
Kazuhiko Nakagawa,Edward B. Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz‐Ares,Chao‐Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin‐Yuan Shih,Kwok Hung Au,Denis Moro‐Sibilot,Sotaro Enatsu,Annamaria H. Zimmermann,Bente Frimodt‐Moller,Carla Visseren‐Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Denis Moro‐Sibilot,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,Martin Reck,Martin Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos Syrigos,Jcm Ho,Kwok‐Hung Au,Silvia Novello,Andrea Ardizzoni,Giulia Pasello,Vanesa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Kazuhiko Nakagawa,Makoto Nishio,Kiyotaka Yoh,Takashi Seto,Fumio Imamura,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Toru Kumagai,Keisuke Aoe,Toru Kumagai,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Keunchil Park,Sang‐We Kim,Young Joo Min,Hyun Woo Lee,Jin‐Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin-Soo Kim,Gyeong‐Won Lee,Sung Yong Lee,Aurelia Alexandru,Anghel Adrian Udrea,Óscar Juan,Ernest Nadal-Alforja,Ignacio Gil‐Bazo,Santiago Ponce-Aix,Luis Paz‐Ares,Belén Rubio‐Viqueira,M. Alonso Garcìa,E. Felip Font,José Fuentes Pradera,J. Coves Sarto,Meng‐Chih Lin,Wu‐Chou Su,Te‐Chun Hsia,Gee‐Chen Chang,Yu‐Feng Wei,Chao‐Hua Chiu,Jin‐Yuan Shih,Jian Su,İrfan Çiçin,Tuncay Göksel,Hakan Harputluoğlu,Özgür Özyılkan,I. von Henning,Sanjay Popat,Olivia Hatcher,Kathryn F. Mileham,Jared D. Acoba,Edward B. Garon,Gabriel Jung,Moses S. Raj,Martin Wj,Shaker R. Dakhil
出处
期刊:Lancet Oncology [Elsevier]
卷期号:20 (12): 1655-1669 被引量:481
标识
DOI:10.1016/s1470-2045(19)30634-5
摘要

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC. Methods This is a worldwide, double-blind, phase 3 trial done in 100 hospitals, clinics, and medical centres in 13 countries. Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases. We randomly assigned eligible patients in a 1:1 ratio to receive oral erlotinib (150 mg/day) plus either intravenous ramucirumab (10 mg/kg) or matching placebo once every 2 weeks. Randomisation was done by an interactive web response system with a computer-generated sequence and stratified by sex, geographical region, EGFR mutation type, and EGFR testing method. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov, NCT02411448, and is ongoing for long-term survival follow-up. Findings Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20·7 months (IQR 15·8–27·2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4–21·6]) than in the placebo plus erlotinib group (12·4 months [11·0–13·5]), with a stratified hazard ratio of 0·59 (95% CI 0·46–0·76; p<0·0001). Grade 3–4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3–4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]). Treatment-emergent serious adverse events were reported in 65 (29%) of 221 patients in the ramucirumab plus erlotinib group and 47 (21%) of 225 in the placebo plus erlotinib group. The most common serious adverse events of any grade in the ramucirumab plus erlotinib group were pneumonia (seven [3%]) and cellulitis and pneumothorax (four [2%], each); the most common in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]). One on-study treatment-related death due to an adverse event occurred (haemothorax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group. Interpretation Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Safety was consistent with the safety profiles of the individual compounds in advanced lung cancer. The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC. Funding Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
unn发布了新的文献求助10
1秒前
梅小七完成签到,获得积分10
1秒前
3秒前
欣慰猕猴桃完成签到,获得积分10
3秒前
huiluowork发布了新的文献求助100
3秒前
细腻梨愁完成签到,获得积分10
4秒前
Pendragon发布了新的文献求助10
4秒前
du发布了新的文献求助10
5秒前
elsazhou完成签到,获得积分10
5秒前
5秒前
num5thWindMaster完成签到,获得积分10
5秒前
轻松水瑶应助科研通管家采纳,获得10
6秒前
6秒前
Orange应助科研通管家采纳,获得30
6秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
深情安青应助科研通管家采纳,获得10
6秒前
所所应助科研通管家采纳,获得10
6秒前
Ava应助科研通管家采纳,获得10
6秒前
Wk发布了新的文献求助10
6秒前
6秒前
斯文寄松发布了新的文献求助10
7秒前
善学以致用应助风追素心采纳,获得10
7秒前
8秒前
NexusExplorer应助du采纳,获得10
8秒前
竹焚完成签到 ,获得积分10
9秒前
杨涵发布了新的文献求助10
10秒前
chen完成签到,获得积分10
10秒前
迟大猫应助个性尔槐采纳,获得10
10秒前
ssss发布了新的文献求助10
11秒前
罗_应助某泽采纳,获得10
11秒前
希望天下0贩的0应助tony采纳,获得10
11秒前
11秒前
11秒前
强强强强完成签到,获得积分10
12秒前
12秒前
13秒前
毛毛球应助Szj采纳,获得10
14秒前
贪玩芫发布了新的文献求助30
14秒前
科研通AI5应助少少少采纳,获得10
14秒前
小二郎应助zimu012采纳,获得10
14秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546676
求助须知:如何正确求助?哪些是违规求助? 3123726
关于积分的说明 9356475
捐赠科研通 2822353
什么是DOI,文献DOI怎么找? 1551369
邀请新用户注册赠送积分活动 723332
科研通“疑难数据库(出版商)”最低求助积分说明 713721